'I am pleased that we delivered against the financial guidance we established at the beginning of 2023. During the year, we made meaningful progress in driving performance across each of our business segments, continued to focus on our balance sheet and liquidity, and made significant progress on our key R&D initiatives, all helping to position the Company for continued growth and performance. We are excited about the positive momentum in our business as we enter 2024 and will continue to prioritize advancing our pipeline, investing in initiatives to continue to drive growth, and positioning the Company for long-term success,' said
Amiselimod (S1P modulator): once-daily oral treatment of mild to moderate ulcerative colitis
Phase 2 study completed enrollment in
RED-C: prevention and delay of first episode of hepatic encephalopathy
Enrollment of one of two global Phase 3 trials completed, with enrollment of the second trial on track and expected to be completed in the first half of 2024
CABTREOTM: first triple combination product for the treatment of acne vulgaris
Received FDA approval on
New Drug Submission was submitted to
Thermage FLX: uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin's surface
Thermage FLX and the TR-4 Return Pad approved by
Clear + Brilliant Touch: fractionated laser device for skin rejuvenation
Planned regulatory submissions on track for
Next Generation Fraxel: fractionated laser device for skin resurfacing
FDA submission planned in Q2 2024 and approval could occur in the second half of 2024
Fourth-Quarter and Full-Year 2023 Revenue Performance
Total reported revenues were
Total reported revenues were
Contact:
Email: ir@bauschhealth.com
Tel: 877-281-6642
Email: Corporate.communications@bauschhealth.com
Tel: 908-541-3785
(C) 2024 Electronic News Publishing, source